ReviewImmunological reviews2026
Complement Activation by Post-Translationally Modified Proteins: Links to Chronic Inflammation and Autoimmunity.
Review in Immunological reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Post-translational modifications (PTMs) of proteins are essential to maintain homeostasis as many cellular processes rely on reversible PTMs. However, several PTMs, particularly irreversible PTMs in the extracellular space, can contribute to tissue dysfunction, inflammation, and may even trigger the development of autoimmunity against PTM-proteins. Such disease-associated PTMs are formed under conditions of metabolic stress, renal failure, smoking, or pollutants. Importantly, several of these PTMs have recently been shown to have the capacity to activate the complement system directly. These PTMs recruit C1q or Ficolin-3, thereby initiating complement activation. This induces on the one hand opsonins for clearance of (cellular) debris and on the other hand the production of inflammatory mediators. In many autoimmune diseases, patients develop a variety of autoantibodies against PTMs, further amplifying complement activation on PTM-proteins. Notably, anti-PTM antibodies are also present, albeit in lower concentrations, in diseases that are not characterized as typical autoimmune diseases. We therefore hypothesize that PTM-driven complement activation is an underlying factor for chronic low-level inflammation, thereby predisposing individuals to cardiovascular and metabolic diseases. In addition, the presence of complement activation fragments on PTM-proteins may facilitate the breakdown of immune tolerance towards PTM-proteins, further facilitating the production of anti-PTM autoantibodies. Finally, several interventions are discussed that either decrease the PTM-proteins or provide targeted complement inhibition specifically on PTM-proteins. Altogether, complement activation by PTM-proteins may represent an underestimated contributor to chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.